Serous ovarian borderline tumors: modern classification and biology

In this article there are considered current views on biology of ovarian serous borderline tumors, there is presented a modern histological classification of 2014, which has undergone some changes. Variants of serous borderline tumors are described in terms of morphology, clinical course and prognosis. Also there is discussed the issue of the pathogenesis in the development of ovarian borderline tumors, the contribution of gene mutations in the occurrence of borderline, poorly or well differentiated ovarian tumors. There are described in details features of morphology of serous borderline tumors, the interrelationship of their occurrence and dedifferentiation in dependence on the molecular and genetic deteriorations. In the article there is considered the microinvasive version of the serous borderline tumors and specified criteria for the establishment of this diagnosis. There are given the definition and characterization of micropapillary serous borderline tumors, there is discussed their impact on the course of the disease and prognosis. The issue of terminology is considered in terms of current views and history.

Download Full-text

Histological classification of mucinous ovarian tumors: inter-observer reproducibility, clinical relevance, and role of genetic biomarkers

Virchows Archiv ◽

10.1007/s00428-020-02939-w ◽

2020 ◽

Author(s):

Catherine Genestie ◽

Aurélie Auguste ◽

Miriam Al Battal ◽

Jean-Yves Scoazec ◽

Sébastien Gouy ◽

...

Keyword(s):

Clinical Relevance ◽

Ovarian Tumors ◽

Histological Classification ◽

Genetic Biomarkers ◽

Mucinous Ovarian Tumors

Download Full-text

Histological Classification of Liver Fibrosis and its Impact on the Postoperative Clinical Course of Patients with Congenital Dilatation of the Bile Duct

Surgery Today ◽

10.1007/s00595-005-3109-1 ◽

2006 ◽

Vol 36 (2) ◽

pp. 151-154 ◽

Cited By ~ 3

Author(s):

Toshimichi Hasegawa ◽

Takuya Kimura ◽

Yoshiyuki Ihara ◽

Masahiro Fukuzawa

Keyword(s):

Bile Duct ◽

Liver Fibrosis ◽

Clinical Course ◽

Histological Classification

Download Full-text

Karl Kahlbaum

10.1093/med/9780190881191.003.0003 ◽

2018 ◽

Author(s):

Edward Shorter ◽

Max Fink

Keyword(s):

Young People ◽

Private Hospital ◽

Clinical Course ◽

Common Cause ◽

Modern Classification ◽

Disease Entities ◽

Atlantic Community

In 1874, Karl Kahlbaum, a German psychiatrist in an obscure private hospital, pulled various symptom pictures together into a single diagnosis: “catatonia.” Kahlbaum had earlier pioneered the modern classification of illness with his concepts of course and outcome as demarcating the various disease entities. He thought that, similar to neurosyphilis, catatonia had a common cause and common clinical course but, unlike neurosyphilis, often a relatively benign outcome. He believed the illness progressed in fixed stages. At the same time, Kahlbaum’s associate, Ewald Hecker, described madness in young people (“hebephrenia”), which became the forbearer of “schizophrenia.” Kahlbaum’s ideas were not immediately accepted: there was a core of true believers, but many psychiatrists in the Atlantic community did not readily take up the diagnosis and remained skeptical that Kahlbaum had done anything other than repackage familiar symptoms in a new and unfamiliar box.

Download Full-text

Role of Retinoblastoma Protein Family (Rb/P105 And Rb2/P130) Expression in the Hystopathological Classification of Borderline Ovarian Tumors

10.21203/rs.3.rs-48452/v1 ◽

2020 ◽

Cited By ~ 1

Author(s):

Valeria Masciullo ◽

Paola Valdivieso ◽

Giulia Amadio ◽

Angela Santoro ◽

Giuseppe Angelico ◽

...

Keyword(s):

Tumor Progression ◽

Cellular Proliferation ◽

Family Members ◽

Ovarian Tumors ◽

Pivotal Role ◽

Borderline Tumors ◽

Cytoplasmic Expression ◽

Borderline Ovarian Tumors ◽

Diagnosis And Classification

Abstract Background Borderline ovarian tumors (BOT) are uncommon but not rare epithelial ovarian neoplasms, intermediate between benign and malignant categories. Emerging knowledge supports the notion that subtypes of borderline ovarian tumors comprise distinct biologic, pathogenetic, and molecular entities, precluding a single unifying concept for BOT. Therefore, the identification of valuable markers for the diagnosis and classification of these tumors is in need. Among the molecular candidates, the Retinoblastoma (Rb) family members Rb/p105 and Rb2/p130 seem to play a pivotal role in ovarian cancer. In particular, Rb/p105, when in the unphosphorylated form, acts as a growth suppressor and plays a pivotal role in the negative control of the cell cycle and in tumor progression; whereas, the phosphorylated form (p-pRB) activates genic transcription and cellular proliferation. While Rb/p105 is ubiquitously confined to the nuclei of cycling and quiescent cells, Rb2/p130 activity is also regulated by intracellular localization. According to this premise, Rb family members could represent a novel marker in diagnosis and classification risk for patients with borderline ovarian tumors (BOT). Aims In this study, we evaluated the immunohistochemical expression and subcellular localization of proteins of the retinoblastoma (Rb) gene family: Rb/p105 and Rb2/p130 in 65 ovarian borderline tumors (26 serous, 19 sero-mucinous and 20 mucinous subtypes). Results Statistically significant differences were found in nuclear and cytoplasmic expression of Rb/p105 and Rb2/p130 according to different examined histotypes. In detail, the nuclear expression of Rb/p105 and Rb2/p130 was more frequently detected in serous (84.6%) than sero-mucinous (42.1%) and mucinous (50%) types. Conversely, the cytoplasmic expression of Rb2/p130 was not detected in serous tumors and frequently observed in mucinous subtypes (80%). Conclusions Our findings suggest that Rb proteins do not play a key role in the tumor progression of serous borderline tumors since they are always located in the nucleus and no cases showed a cytoplasmic localization. By contrast, the observed higher cytoplasmic expression of Rb2/p130 in mucinous BOTs (intestinal) types, is suggestive of Rb proteins involvement in the cancerogenesis pathway of mucinous ovarian tumors. Our results also suggest that mucinous BOTs of intestinal type, exhibiting low nuclear and high cytoplasmic levels of Rb2/p130 might potentially be considered a high risk category of malignant evolution. Further studies on larger series are needed in order to clarify how BOTs could be stratified in different prognostic groups according to their Rb proteins immunohistochemical profile.

Download Full-text